Stocks
argenx SEARGX
NASDAQHealthcareBiotechnology$700.45-1.19%
Focused on developing antibody-based therapies for autoimmune diseases and cancer, argenx SE is a global immunology company with a strong pipeline of innovative treatments. Investors track its progress due to the potential of its lead product, Vyvgart, in treating rare autoimmune conditions and its collaborations with major pharmaceutical firms.
Market Cap: $43.3B52W Range: $510.06 – $934.62
Congressional Interest in argenx SE (ARGX)
2 members of Congress have disclosed 2 trades in argenx SE (ARGX), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
2
Unique Politicians
2
Buys
1
Sells
1
Who in Congress Is Trading ARGX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2026-03-30 | Alan Armstrong | buy | $1K – $15K |
| 2023-07-10 | Daniel Goldman | sell | $1K – $15K |